Cleveland Biolabs' (CBLI) CBLB502 gets fast track status from FDA
- Top 10 News Items for 05/20 to 05/24: A True Fed Tapering?, Japan's Nikkei Blasted, Dimons are Forever
- Valeant (VRX) Continues Deal Hunt; Close to Buying Bausch & Lomb for $9B
- A.G. Lafley Returns as President/CEO of Procter & Gamble (PG)
- Chile Slaps Barrick Gold (ABX) with $16.4M Fine, Halts Construction at Pascua-Lama
- StreetInsider.com Pre-Open Movers 5/24: (BLOX) (IOC) (P) Higher; (RSOL) (SHLD) (ANF) Lower (more...)
Cleveland Biolabs' (Nasdaq: CBLI) CBLB502 gets fast track status from FDA
You May Also Be Interested In
- Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- Tessera (TSRA), Starboard Reach Agreement Over Board Composition
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot List
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!